Hypogonadism risk in men treated for childhood cancer.
BACKGROUND
Pediatric cancer treatment may imply an increased risk of hypogonadism, leading to metabolic disorders and osteoporosis. Such complications are potentially preventable.


OBJECTIVE
The aim of this study was to assess diagnosis- and treatment-dependent risk of hypogonadism in male childhood cancer survivors (CCS).


METHODS
Male CCS who were treated during the period 1970-2002 and who in 2004 were 18-45 yr of age were eligible.


METHODS
The study was conducted in a university hospital clinic.


METHODS
A consecutive group of CCS treated at Lund University Hospital was selected for the study, of whom 151 (38%) agreed to participate. Furthermore, 141 healthy fertile men served as controls.


METHODS
We measured serum levels of free and total testosterone, SHBG, and LH.


METHODS
Odds ratios (OR) for biochemical hypogonadism, defined as total testosterone less than 10 nmol/liter and/or LH above 10 IU/liter, were calculated and related to type of cancer, treatment received, as well as testicular volume.


RESULTS
Hypogonadism was more commonly detected in CCS than in controls (OR, 6.7; 95% CI, 2.7, 17). The increased presence of hypogonadism was noted in the following treatment groups: brain surgery, chemotherapy (with and without radiotherapy), and testicular irradiation. Low total testicular volume (<or=24 ml) was associated with a high risk of hypogonadism (OR, 31; 95% CI, 11, 92).


CONCLUSIONS
Adult male survivors of childhood cancer are at risk of hypogonadism, which should be acknowledged in the long-term follow-up of these men.
Departments of Pediatrics, Lund University Hospital, Lund SE-221 85, Sweden.
Patrik
P
Romerius
Olof
O
Ståhl
Christian
C
Moëll
Thomas
T
Relander
Eva
E
Cavallin-Ståhl
Thomas
T
Wiebe
Yvonne Lundberg
YL
Giwercman
Aleksander
A
Giwercman
D000328:Adult; D001932:Brain Neoplasms / Q000628:therapy; D005298:Fertility; D005500:Follow-Up Studies; D006785:Hospitals, University; D006801:Humans; D007006:Hypogonadism / Q000097:blood / Q000453:epidemiology*; D007680:Kidney Neoplasms / Q000628:therapy; D007938:Leukemia / Q000628:therapy; D007986:Luteinizing Hormone / Q000097:blood; D008223:Lymphoma / Q000628:therapy; D008297:Male; D009369:Neoplasms / Q000628:therapy*; D016017:Odds Ratio; D012016:Reference Values; D012307:Risk Factors; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D017741:Survivors / Q000706:statistics & numerical data*; D013736:Testicular Neoplasms / Q000628:therapy; D013739:Testosterone / Q000097:blood; D009396:Wilms Tumor / Q000628:therapy; D055815:Young Adult
D012738:Sex Hormone-Binding Globulin; D013739:Testosterone; D007986:Luteinizing Hormone